Lannett is continuing to bank on a series of potentially high-value pipeline products – including two insulin biosimilars and a trio of complex respiratory generics – as well as certain nearer-term launches to reverse the downward trajectory seen for the company’s sales and profits.
“Ongoing competitive pressures” and rising rates of returns led the firm to further declines in its financial third quarter ended...







